

DAFTAR PUSTAKA

- Aberg, J. A., Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). *Drug Information Handbook* (17th edition). Lexi-Comp for the American Pharmacists Association.
- Amelia, R., Hasanuddin, S., & Herlina Nasir, N. (2025). Analisis Drug Related Problems Penggunaan Antibiotik Pada Pasien Anak dengan Diare di BLU RSUD Kabupaten Bombana Periode Januari – Juli Tahun 2023. *Jurnal Pharmacia Mandala Waluya*, 4(1), 45–55. <https://doi.org/10.54883/jpmw.v4i1.244>
- American Psychiatric Association. (2022). *Diagnostic And Statistical Manual Of Mental Disorders* 5.
- Andayani, T. M., Rahmawati, F., & Rokhman, M. R. (2020). *Drug related problems: identifikasi, faktor resiko dan pencegahannya*.
- Angst, J., Paksarian, D., Cui, L., Merikangas, K. R., Hengartner, M. P., Ajdacic-Gross, V., & Rössler, W. (2016). The epidemiology of common mental disorders from age 20 to 50: Results from the prospective Zurich cohort Study. *Epidemiology and Psychiatric Sciences*, 25(1), 24–32. <https://doi.org/10.1017/S204579601500027X>
- Ansara, E. D. (2020). Management of treatment-resistant generalized anxiety disorder. In *Mental Health Clinician* (Vol. 10, Issue 6, pp. 326–334). Allen Press Inc. <https://doi.org/10.9740/mhc.2020.11.326>
- Archer, C., Wiles, N., Kessler, D., Turner, K., & Caldwell, D. M. (2025a). Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. *Journal of Affective Disorders*, 368, 90–99. <https://doi.org/10.1016/j.jad.2024.09.068>
- Archer, C., Wiles, N., Kessler, D., Turner, K., & Caldwell, D. M. (2025b). Beta-blockers for the treatment of anxiety disorders: A systematic review and meta-analysis. *Journal of Affective Disorders*, 368, 90–99. <https://doi.org/10.1016/j.jad.2024.09.068>
- Armstrong, C., & Kapelowicz, M. R. (2020). A Preliminary Investigation on the Effects of Atenolol for Treating Symptoms of Anxiety. *Military Medicine*, 185(11–12), E1954–E1960. <https://doi.org/10.1093/milmed/usaa170>

Asqiya, A., Ningrum, W. A., Muthoharoh, A., & Permadi, Y. W. (2023). *Pengaruh Penggunaan Obat Pada Pasien Depresi Terhadap Keberhasilan Obat Secara Subyektif Di RPSBM Kota Pekalongan*. 6.

Badan Penelitian dan Pengembangan Kesehatan. (2019). *Laporan Nasional Riset Kesehatan Dasar 2018*.

Brueckle, M. S., Thomas, E. T., Seide, S. E., Pilz, M., Gonzalez-Gonzalez, A. I., Nguyen, T. S., Harder, S., Glasziou, P. P., Gerlach, F. M., & Muth, C. (2020). Adverse drug reactions associated with amitriptyline - Protocol for a systematic multiple-indication review and meta-analysis. *Systematic Reviews*, 9(1). <https://doi.org/10.1186/s13643-020-01296-8>

Bushnell, G. A., Rynn, M. A., Crystal, S., Gerhar, T., & Olfson, M. (2021). Simultaneous Benzodiazepine and SSRI Initiation in Young People With Anxiety Disorders. *Journal of Clinical Psychiatry*, 82(6). <https://doi.org/10.4088/JCP.20M13863>

Chatterjee, S., Kar, S. K., Prakash, A. J., Bansal, T., & Singh, G. (2023). Drug-drug interaction between psychotropic medications and medications used in COVID-19: Comparison of online databases. *Clinical Psychopharmacology and Neuroscience*, 21(3), 534–543. <https://doi.org/10.9758/cpn.22.1014>

Chisholm-Burns, M. A., Schwinghammer, T. L., & Malone, P. M. (2022). *Pharmacotherapy Principles And Practice*.

Davidson, J. R., Zhang, W., Connor, K. M., Ji, J., Jobson, K., Lecrubier, Y., McFarlane, A. C., Newport, D. J., Nutt, D. J., Osser, D. N., Stein, D. J., Stowe, Z. N., Tajima, O., & Versiani, M. (2010). Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD). In *Journal of Psychopharmacology* (Vol. 24, Issue 1, pp. 3–26). <https://doi.org/10.1177/0269881108096505>

De Lijster, J. M., Dierckx, B., Utens, E. M. W. J., Verhulst, F. C., Zieldorff, C., Dieleman, G. C., & Legerstee, J. S. (2017). The age of onset of anxiety disorders: A meta-analysis. In *Canadian Journal of Psychiatry* (Vol. 62, Issue 4, pp. 237–246). SAGE Publications Inc. <https://doi.org/10.1177/0706743716640757>

Diksis, N., Melaku, T., Assefa, D., & Tesfaye, A. (2019). Potential drug–drug interactions and associated factors among hospitalized cardiac patients at Jimma University Medical Center, Southwest Ethiopia. *SAGE Open Medicine*, 7. <https://doi.org/10.1177/2050312119857353>

Drugs.com. (2025). *Drug Interaction Checker*. https://www.drugs.com/drug_interactions.html

- Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., Cornett, E. M., & Kaye, A. M. (2021). Selective serotonin reuptake inhibitors and adverse effects: A narrative review. In *Neurology International* (Vol. 13, Issue 3, pp. 387–401). MDPI AG. <https://doi.org/10.3390/neurolint13030038>
- Farhane-Medina, N. Z., Luque, B., Tabernero, C., & Castillo-Mayén, R. (2022). Factors associated with gender and sex differences in anxiety prevalence and comorbidity: A systematic review. In *Science Progress* (Vol. 105, Issue 4). SAGE Publications Ltd. <https://doi.org/10.1177/00368504221135469>
- Fisher, K., Rice, S. M., Oliffe, J. L., King, K., & Seidler, Z. E. (2023). Young men and anxiety: Resisting, reckoning and responding. *Sociology of Health and Illness*, 45(7), 1462–1482. <https://doi.org/10.1111/1467-9566.13641>
- G. Katsioulis, E., Argyraki, M., T. Ekonomopoulou, M., Mourelatos, C., Iakovidou-Kritsi, Z., & Mourelatos, D. (2020). Typical versus atypical antipsychotics: Genotoxicity and cytostaticity testing. *Integrative Cancer Science and Therapeutics*, 7(3). <https://doi.org/10.15761/icst.1000340>
- Goldschen-Ohm, M. P. (2022). Benzodiazepine Modulation of GABAA Receptors: A Mechanistic Perspective. In *Biomolecules* (Vol. 12, Issue 12). MDPI. <https://doi.org/10.3390/biom12121784>
- Gołyszny, M., & Obuchowicz, E. (2019). Are neuropeptides relevant for the mechanism of action of SSRIs? In *Neuropeptides* (Vol. 75, pp. 1–17). Churchill Livingstone. <https://doi.org/10.1016/j.npep.2019.02.002>
- Grinchii, D., & Dremencov, E. (2020). Mechanism of action of atypical antipsychotic drugs in mood disorders. In *International Journal of Molecular Sciences* (Vol. 21, Issue 24, pp. 1–15). MDPI AG. <https://doi.org/10.3390/ijms21249532>
- Guelfi, J. D., Pichot, P., & Dreyfus, J. F. (1998). Efficacy of Tianeptine in Anxious-Depressed Patients: Results of a Controlled Multicenter Trial versus Amitriptyline. *Neuropsychobiology*, 22, 41–48.
- Joint Formulary Committee. (2021). *BNF 82*. BMJ Group. www.sps.nhs.uk/ukdilas
- Kartika, E. (2023). *Evaluasi Kesesuaian Penggunaan Obat Anticemas Pada Pasien Gangguan Cemas Menyeluruh Di Poli Jiwa Rawat Jalan Rumah Sakit Swasta X Kota Bekasi Periode 2022, Skripsi*.
- Kementerian Kesehatan Republik Indonesia. (2021). *Angka gangguan kecemasan naik 6,8 persen selama pandemi*.

<https://www.antaranews.com/berita/2444893/kemenkes-angka-gangguan-kecemasan-naik-68-persen-selama-pandemi>

- Krieger, A. (2025). Benzos (as) needed: research into as-needed and intermittent benzodiazepines for anxiety is required for comprehensive best prescribing practices. In *Frontiers in Psychiatry* (Vol. 16). Frontiers Media SA. <https://doi.org/10.3389/fpsy.2025.1569416>
- Kundakovic, M., & Rocks, D. (2022). Sex hormone fluctuation and increased female risk for depression and anxiety disorders: From clinical evidence to molecular mechanisms. In *Frontiers in Neuroendocrinology* (Vol. 66). Academic Press Inc. <https://doi.org/10.1016/j.yfne.2022.101010>
- Lapierre, Y. D., Tremblay, A., Gagnon, A., Monpremier, P., Berliss, H., & Oyewumi, L. (1982). A therapeutic and discontinuation study of clobazam and diazepam in anxiety neurosis. *The Journal of Clinical Psychiatry*, 43(9), 372–374. <https://psycnet.apa.org/record/1983-13278-001>
- Liu, D., Zhang, Q., Zhao, Z., Chen, M., Hou, Y., Wang, G., Shen, H., Zhu, H., Ji, Y., Ruan, L., & Lou, Z. (2023). Benzodiazepine-Receptor Agonist Utilization in Outpatients with Anxiety Disorder: A Retrospective Study Based on Electronic Healthcare Data from a Large General Tertiary Hospital. *Healthcare (Switzerland)*, 11(4). <https://doi.org/10.3390/healthcare11040554>
- Maimanah, S., Dwi Andarini, Y., & Kusumaningtyas, N. M. (2020). Identifikasi Drug Related Problems (DRPs) Pada Pasien Diabetes Mellitus Tipe 2 Komplikasi Hipertensi Di RSUP Dr. Soeradji Tirtonegoro Klaten Tahun 2018. In 48 | *Pharmasipha* (Vol. 4, Issue 2).
- Marasine, N. R., & Sankhi, S. (2021). Factors associated with antidepressant medication non-adherence. In *Turkish Journal of Pharmaceutical Sciences* (Vol. 18, Issue 2, pp. 242–249). Turkish Pharmacists Association. <https://doi.org/10.4274/tjps.galenos.2020.49799>
- Medscape. (2025). *Drug Interaction Checker*. <https://reference.medscape.com/drug-interactionchecker>
- Melaragno, A. J. (2021). Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance. *Focus*, 19(2), 145–160. <https://doi.org/10.1176/appi.focus.20200048>
- Melton, S. T., & Kirkwood, C. K. (2020). *Pharmacotherapy A Pathophysiologic Approach Eleventh Edition* (J. T. Dipiro, G. C. Yee, & M. Posey, Eds.; pp. 3393–3394). McGraw Hill.

- Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, Sebastian JA, Semchyshyn G, Durr MJ, & Melmed AS. (1986). Effective short-term treatment of generalized anxiety disorder with trifluoperazine. *J Clin Psychiatry*, 47(4), 170–174. <https://pubmed.ncbi.nlm.nih.gov/3514583/>
- Mendra, N. N. Y., Ikawati, Z., & Kristanto, C. S. (2021). Efektivitas dan Keamanan Terapi Benzodiazepin pada Pasien Gangguan Ansietas dengan Riwayat Penyalahgunaan Obat. *Jurnal Farmasi Klinik Indonesia*, 10(3), 190–197. <https://doi.org/10.15416/ijcp.2021.10.3.190>
- Mishra, A. K., & Varma, A. R. (2023). A Comprehensive Review of the Generalized Anxiety Disorder. *Cureus*. <https://doi.org/10.7759/cureus.46115>
- Mulyo, D. L. (2015). *Studi Penggunaan Obat Anticemas Pada Pasien Gangguan Cemas Menyeluruh (Penelitian dilakukan di Poli Jiwa RSUD Dr. Soetomo Surabaya)*. Universitas Airlangga.
- Muniyanti, A. (2022). *Skripsi: Evaluasi Penggunaan Obat Pada Pasien Depresi Di Rumah Sakit Jiwa DR. Soeharto Heerdjan Jakarta Periode 2020*.
- Mursyid, M. A., & Mohaidin, Z. (2017). Models and theories of prescribing decisions: A review and suggested a new model. In *Pharmacy Practice* (Vol. 15, Issue 2). Grupo de Investigacion en Atencion Farmaceutica. <https://doi.org/10.18549/PharmPract.2017.02.990>
- Nugsria, A., Pratitis, N. T., Arifiana, I. Y., & Psikologi, F. (2023). Quarter life crisis pada dewasa awal: Bagaimana peranan kecerdasan emosi? *INNER: Journal of Psychological Research*, 3(1), 1–10.
- Nurvianthi, R. Y., Djafar, T., Jehanam, T., Safitri, A., Studi Farmasi, P., Bhakti Pertiwi Luwu Raya Palopo, S., Studi Gizi, P., & Studi Keperawatan Stikes Bhakti Pertiwi Luwu Raya Palopo Jl Andi, P. (2024). *Analisis penggunaan obat resep dokter pasien Generalized Anxiety Disorder (GAD) di RSUD Andi Djemma Masamba Analysis of the use of prescribed medication by patients with Generalized Anxiety Disorder (GAD) at RSUD Andi Djemma Masamba*. 8(2). <https://doi.org/10.21111/pharmasipha.v8i2>
- Park, C., Son, A.-H., Shin, A.-H., Choi, A.-K., Tinggi, S., Universitas, F., Sookmyung, W., Peninjauan, L., Asuransi, P., Korea, K., Tinjauan, S., Obat, P., Tentang, R., Terapi Pada Pasien, D., Kecemasan, G., Park, C. H., Sohn, H. S., Shin, H. T., Choi, K. E., ... Kesehatan, A. (2010). Sebuah studi evaluasi penggunaan obat secara retrospektif terhadap duplikasi terapi pada pasien dengan gangguan kecemasan. In *Jurnal Masyarakat Farmasi Klinis Korea* (Vol. 20, Issue 1). www.DeepL.com/pro

Pharmaceutical Care Network Europe. (2019). *PCNE V9.00 Bahasa Indonesia Versi Indonesia*.

Pichini, S., Di Trana, A., García-Algar, O., & Busardò, F. P. (2023). Editorial: Drug-drug interactions in pharmacology. In *Frontiers in Pharmacology* (Vol. 14). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2023.1155738>

Pollack, M. H., Simon, N. M., Zalta, A. K., Worthington, J. J., Hoge, E. A., Mick, E., Kinrys, G., & Oppenheimer, J. (2006). Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. *Biological Psychiatry*, 59(3), 211–215. <https://doi.org/10.1016/j.biopsych.2005.07.005>

Pratama, T. D., & Maulana, R. (2024). *54 Drug Related Problems (DRPs) Pada Pasien Depresi Di Instalasi Rawat Inap Rumah Sakit Jiwa Prof. Dr Soerojo Magelang Jawa Tengah Drug Related Problems (DRPs) In Depression Patients At The Inpatient Installation Of The Prof. Soerojo Soul Hospital. Dr. Soerojo Magelang Central Java* (Vol. 7, Issue 1).

Putri, I. A., Amnan, & Maharani, B. F. (2022). Profil Penggunaan Antipsikotik Dan Antiansietas Pada Pasien Skizofrenia Rawat Inap Di Rumah Sakit Jiwa Mutiara Sukma Provinsi NTB Tahun 2021. In *Journal of Village and Local Community* (Vol. 1).

Rabbani, M. Q., Palloge, S. A., Susanto, H. F., Isrea, N., & Santy, I. (2024). Karakteristik dan Faktor Risiko Pasien Gangguan Kecemasan Tahun 2022. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, 4(3). <https://fmj.fk.umi.ac.id/index.php/fmj>

Rahman, Q., & Oktavilantika, D. M. (2023). *Profil Penggunaan Obat Antidepresan Pada Pasien Gangguan Ansietas Di Rumah Sakit Bhayangkara Indramayu Pada Tahun 2021* (Vol. 1, Issue 2).

Rasool, M. F., ur Rehman, A., Khan, I., Latif, M., Ahmad, I., Shakeel, S., Sadiq, M., Hayat, K., Shah, S., Ashraf, W., Majeed, A., Hussain, I., & Hussain, R. (2023). Assessment of risk factors associated with potential drug-drug interactions among patients suffering from chronic disorders. *PLoS ONE*, 18(1 January). <https://doi.org/10.1371/journal.pone.0276277>

Ren, W., Liu, Y., Zhang, J., Fang, Z., Fang, H., Gong, Y., & Lv, X. (2020). Prevalence of potential drug–drug interactions in outpatients of a general hospital in China: a retrospective investigation. *International Journal of Clinical Pharmacy*, 42(4), 1190–1196. <https://doi.org/10.1007/s11096-020-01068-3>

- Republik Indonesia. (2015). *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/73/2015 Tentang Pedoman Nasional Pelayanan Kedokteran Jiwa*.
- Rikomah, S. E. (2018). *Farmasi Klinik*. Deepublish Publisher .
- Rinaldi, A., Bullo, A., & Schulz, P. J. (2025). Patients' requests and physicians' prescribing behavior. A systematic review. In *Patient Education and Counseling* (Vol. 136). Elsevier Ireland Ltd. <https://doi.org/10.1016/j.pec.2025.108747>
- Ritter, J. M., Flower, R., Henderson, G., & Loke, Y. K. (2020). *Rang And Dales's Pharmacology Ninth Edition*. Elsevier.
- Riyanto, S., & Hatmawan, A. A. (2020). *Metode Riset Penelitian Kuantitatif*.
- RS Soeharto Heerdjan. (2025). *Visi dan Misi Rumah Sakit Jiwa Soeharto Heerdjan*. <https://rsjsh.co.id/visi-dan-misi>
- Ruscio, A. M., Hallion, L. S., Lim, C. C. W., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Andrade, L. H., Borges, G., Bromet, E. J., Bunting, B., De Almeida, J. M. C., Demyttenaere, K., Florescu, S., De Girolamo, G., Gureje, O., Haro, J. M., He, Y., Hinkov, H., Hu, C., ... Scott, K. M. (2017). Cross-sectional comparison of the epidemiology of DSM-5 generalized anxiety disorder across the globe. *JAMA Psychiatry*, 74(5), 465–475. <https://doi.org/10.1001/jamapsychiatry.2017.0056>
- Sari, O. M., Maulana, A., & Putra, P. (2024). *Severity and Risk Rating of Drug-Drug Interaction Potency in Chronic Kidney Disease in Public Health Hospital*.
- Schindler, E., Richling, I., & Rose, O. (2021). Pharmaceutical Care Network Europe (PCNE) drug-related problem classification version 9.00: German translation and validation. *International Journal of Clinical Pharmacy*, 43(3), 726–730. <https://doi.org/10.1007/s11096-020-01150-w>
- Showraki, M., Showraki, T., & Brown, K. (2020). Generalized Anxiety Disorder: Revisited. *Psychiatric Quarterly*, 91(3), 905–914. <https://doi.org/10.1007/s11126-020-09747-0>
- Silberman, E., Balon, R., Starcevic, V., Shader, R., Cosci, F., Fava, G. A., Nardi, A. E., Salzman, C., & Sonino, N. (2021). Benzodiazepines: It's time to return to the evidence. In *British Journal of Psychiatry* (Vol. 218, Issue 3, pp. 125–127). Cambridge University Press. <https://doi.org/10.1192/bjp.2020.164>

- Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, & Pollack MH. (2006). An open-label trial of risperidone augmentation for refractory anxiety disorders. *J Clin Psychiatry*, 67(3), 381–385. <https://doi.org/10.4088/jcp.v67n0307>
- Şimşek, A., Taner, N., Macit, Ç., Berk, B., & Mercanoğlu, G. (2019). The Importance of Computerized Drug Interaction Checker Programs Used in Community Pharmacies to Avoid Potential Drug Interactions: A Preliminary Study with Clarithromycin. *Istanbul Medical Journal*, 20(1), 67–71. <https://doi.org/10.4274/imj.galenos.2018.45712>
- Stein, M. B., & Sareen, J. (2015). CLINICAL PRACTICE. Generalized Anxiety Disorder. *The New England Journal of Medicine*, 373(21), 2059–2068. <https://doi.org/10.1056/NEJMcp1502514>
- Strawn, J. R., Geraciotti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018). Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. *Expert Opinion on Pharmacotherapy*, 19(10), 1057–1070. <https://doi.org/10.1080/14656566.2018.1491966>
- Sunarti. (2020). *Drugs Interaction in Clinical Management for (Generalized Anxiety Disorders) Inpatients: A Retrospective Study*. www.drugs.com
- Taghy, N., Cambon, L., Cohen, J. M., & Dussart, C. (2020). Failure to reach a consensus in polypharmacy definition: An obstacle to measuring risks and impacts—results of a literature review. In *Therapeutics and Clinical Risk Management* (Vol. 16, pp. 57–73). Dove Medical Press Ltd. <https://doi.org/10.2147/TCRM.S214187>
- Tallarida, R. J. (2015). Quantitative Methods for Assessing Drug Synergism. In *Genes and Cancer* (Vol. 2, Issue 11, pp. 1003–1008). <https://doi.org/10.1177/1947601912440575>
- Tavousi, F., Sadeghi, A., Darakhshandeh, A., & Moghaddas, A. (2019). Potential Drug-drug Interactions at a Referral Pediatric Oncology Ward in Iran: A Cross-sectional Study. In *J Pediatr Hematol Oncol* (Vol. 41, Issue 3). www.jpoho-online.com
- Taylor, D. L. (2016). *Prinsip dan Praktik Keperawatan Kesehatan Jiwa Stuart Edisi Indonesia Ke-2* (Gail. W. Stuart, Ed.). Elsevier.
- World Health Organization. (2023). *Anxiety Disorders*. [https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders#:~:text=Anxiety%20disorders%20interfere%20with%20daily,an%20anxiety%20disorder%20\(1\).](https://www.who.int/news-room/fact-sheets/detail/anxiety-disorders#:~:text=Anxiety%20disorders%20interfere%20with%20daily,an%20anxiety%20disorder%20(1).)

- Wulandari, P., & Hidayat, R. (2020). General anxiety disorder-related coronavirus disease-19 outbreak in Indonesia: A case report. *Open Access Macedonian Journal of Medical Sciences*, 8(T1), 36–38. <https://doi.org/10.3889/oamjms.2020.4762>
- Yuan, S., & Chen, H. (2019). Mathematical rules for synergistic, additive, and antagonistic effects of multi-drug combinations and their application in research and development of combinatorial drugs and special medical food combinations. *Food Science and Human Wellness*, 8(2), 136–141. <https://doi.org/10.1016/j.fshw.2019.01.003>
- Zaltzman, D. A. (1976). Amitriptyline hydrochloride in the treatment of anxiety and insomnia and as a tranquilizer. *Neurol Neurocir Psiquiatr*, 17(3), 165–169.